Jupiter Life Line Hospitals Limited
Jupiter Life Line Hospitals Limited operates in Hospital, part of the Healthcare sector. It booked ₹456 cr of revenue in its latest quarter (Q2 FY27) and kept 12.3% of sales as profit.
“is to be the To give patient and his most comprehensive, family a clear advantage transparent and to win their war against cost-effective healthcare disease by creating the best solution provider in infrastructure, technology the region.”
Healthier than 53% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 118–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 55
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in JLHL?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹456 cr |
| Other Income | ₹11 cr |
| Total Income | ₹467 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹84 cr |
| Inventory Change (±) | ₹2 cr |
| Employee Benefit Expense | ₹81 cr |
| Finance Costs | ₹14 cr |
| Depreciation & Amortisation | ₹28 cr |
| Other Expenses | ₹182 cr |
| Total Expenses | ₹392 cr |
| Profit before Tax | ₹75 cr |
| Tax Expense | ₹19 cr |
| Net Profit | ₹56 cr |
| Net margin on total income | 12.1% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 388 cr | 411 cr | 456 cr |
| Total income | 397 cr | 422 cr | 467 cr |
| Expenses | 331 cr | 371 cr | 392 cr |
| Profit before tax | 66 cr | 51 cr | 75 cr |
| Tax | 17 cr | 13 cr | 19 cr |
| Net profit (owners' share) | 51 cr | 37 cr | 56 cr |
| Net margin (owners' share, on revenue) | 13.1% | 9.1% | 12.3% |
| EPS (₹) | 7.66 | 5.72 | 1.72 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹8,440 | ₹1.21 L cr | 52.2 | 24.5% | 8.2% | — |
| Max Healthcare Institute Limited | ₹896 | ₹87,160 cr | 52.6 | 14.6% | 16.2% | — |
| Manipal Health Enterprises Limited | ₹642 | ₹75,740 cr | 81.9 | — | 7.5% | — |
| Fortis Healthcare Limited | ₹786 | ₹59,306 cr | 55.6 | 10.8% | 10.5% | — |
| Narayana Hrudayalaya Ltd. | ₹1,871 | ₹38,228 cr | 31.6 | 24.1% | 10.6% | — |
| Global Health Limited | ₹1,326 | ₹35,621 cr | 40.4 | 20.3% | 14.9% | — |
| Aster DM Quality Care Limited | ₹681 | ₹35,303 cr | 549.5 | 1.4% | 1.2% | — |
| Krishna Institute of Medical Sciences Limited | ₹731 | ₹30,681 cr | 175.6 | 7.4% | 3.5% | — |
| Dr. Agarwal's Health Care Limited | ₹513 | ₹16,256 cr | 89.7 | 8.9% | 7.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Stock split | Stock Split From Rs.10/- to Rs.2/- | 24 Jul 2026 |
| Dividend | ₹1 / share | 22 May 2026 |
| Dividend | ₹1 / share | 4 Jul 2025 |
| Dividend | ₹1 / share | 2 Aug 2024 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 17 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.